If you have been reading about GIP receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-01. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The second group are criteria insensitive for minimal difference between RF values (if two compounds are not separated, such CRF functions will not indicate it). They are equal to zero in equal-spread state increase when situation is getting worse. There are:
Bennie and colleagues proposed a method for chemical euthanasia of insects and other terrestrial arthropods. As of 2024, the Insect Welfare Research Society guidelines for protecting and promoting insect welfare in research recommend chemical agents, rapid freezing, immersion in alcohol following anesthesia, or crushing/grinding as methods that may humanely euthanize insects. Insect welfare is currently not regulated in research settings, resulting in the frequent reporting of some low-welfare practices such as vivisection (live dissection of an animal without anesthetics) in the discipline. Recent research suggests that the Canadian public believes insect welfare in research should be regulated to 2/3rds the level of oversight given to vertebrates. Some authors, including animal ethicists and academics that research insect farming, have begun extending discussions of insect welfare beyond the laboratory to the domain of raising insects for food, feed, or pet food. The Dutch Animal Act, which went into effect on 1 January 2013, created a regulatory framework for farm-animal welfare based on the Five Freedoms, and the law specifically lists a number of insect species as "production animals" whose wellbeing needs to be respected. Dutch politician Marianne Thieme asked a series of questions suggesting concern that insect farming would multiply the number of animals farmed and killed for human consumption.
With this new logo, Outback then went on an aggressive remodeling campaign, starting in 2008, renovating most of their locations, along with opening brand new ones, for a fresher, more modern look to their business model. This included the removal of their iconic neon signs for more energy efficient LEDs, and the switch from a dark, rustic feel to a brighter, more vibrant look. Today, few original-style Outback locations remain, with most of them either abandoned for newer locations, or renovated. On June 14, 2007, OSI Restaurant Partners completed a stock repurchase plan, and the company became privately held. In April 2012, Bloomin' Brands, the current owner of Outback Steakhouse, filed with the SEC to raise up to $300 million in an initial public offering. Bloomin' Brands, Inc. became a publicly traded company on NASDAQ under the ticker symbol "BLMN." Most Outback locations are corporately owned by Bloomin Brands. However, locations in California, Nevada, Arizona, Colorado, and New Mexico are separately owned by a corporate franchisee, Out West Restaurant Group. Outback Steakhouse currently operates over 1,000 locations worldwide, with 670 in the United States. In October 2025, Outback Steakhouse closed several locations across multiple U.S. states as part of a broader turnaround plan by its parent company, Bloomin' Brands.
Noriega's relationship with the U.S. deteriorated further during the late 1980s, particularly after the U.S. began to suspect that Noriega was supporting other intelligence services. Hersh wrote in 1986 that U.S. intelligence officials suspected that Noriega was selling intelligence to the Cuban government of Fidel Castro; his report received widespread attention. Bob Woodward published a story about Noriega in The Washington Post soon afterward, going into even greater detail about Noriega's intelligence connections. Woodward and Hersh's reputations made certain that the stories were taken seriously. Spadafora had also informed the U.S. Drug Enforcement Administration (DEA) of some of his findings about Noriega's involvement in drug smuggling. Multiple U.S. agencies continued to investigate Noriega despite opposition from the Reagan administration. In 1988 Noriega was indicted by U.S. federal grand juries in courts in Miami and Tampa on charges of drug-trafficking. The indictment accused him of "turning Panama into a shipping platform for South American cocaine that was destined for the U.S., and allowing drug proceeds to be hidden in Panamanian banks". Soon afterward an army colonel and a few soldiers made an attempt to overthrow Noriega; their poorly planned effort was crushed within a day. The presidential election of May 1989 was marred by fraud and violence. Coalición para la Liberación Nacional (Coalition for National Liberation), a pro-military coalition led by the PRD, named Carlos Duque, a former business partner of Noriega, as its candidate.
{\displaystyle {\begin{aligned}M_{\mathrm {n} }&={\frac {\sum M_{i}N_{i}}{\sum N_{i}}}&&M_{\mathrm {w} }={\frac {\sum M_{i}^{2}N_{i}}{\sum M_{i}N_{i}}}\\M_{\mathrm {z} }&={\frac {\sum M_{i}^{3}N_{i}}{\sum M_{i}^{2}N_{i}}}&&M_{\mathrm {v} }=\left[{\frac {\sum M_{i}^{1+a}N_{i}}{\sum M_{i}N_{i}}}\right]^{\frac {1}{a}}\end{aligned}}}
Sources: en.wikipedia.org
Rebimastat is a broad spectrum MMP inhibitor with a thiol zinc-binding group. It has oral bioavailability and is a collagen non-peptide mimetic. Rebimastat has some selectivity as it doesn't inhibit all the MMPs operations. The metalloproteinases that release TNF-alpha, TNF-II, L-selectin, IL-1-RII and IL-6 are for example not inhibited by Rebimastat. In phase I of clinical trials, there was no sign of dose-dependent joint toxicity and a disease stabilization. Arthralgia was noted in phase II early breast cancer trials, which was connected to MMP inhibitor toxicity. Rebimastat was used in a Paclitaxel/Carboplatin treatment in phase III. The results of the trial was a higher incidence of adverse reactions, without survival benefit.
US Health Physics Society United Nations "Human rights and weapons of mass destruction, or with indiscriminate effect, or of a nature to cause superfluous injury or unnecessary suffering" (The UN 2002 report) Depleted Uranium and the IAEA Scientific reports ATSDR – Case Studies in Environmental Medicine (CSEM): Uranium Toxicity Archived 4 February 2016 at the Wayback Machine U.S. Department of Health and Human Services "Depleted Uranium in Bosnia and Herzegovina – Postconflict Assessment" Archived 25 February 2012 at the Wayback Machine by UN Environment Programme "Radiological Conditions in Areas of Kuwait With Residues of Depleted Uranium" by International Atomic Energy Agency "Technical Report on Capacity-building for the Assessment of Depleted Uranium in Iraq" Archived 9 March 2012 at the Wayback Machine by UN Environment Programme "A Review of the Scientific Literature As It Pertains to Gulf War Illnesses" by RAND Depleted Uranium article from the Royal Society (archived) An Analysis of Uranium Dispersal and Health Effects Using a Gulf War Case Study by Sandia National Laboratories Depleted Uranium Human Health Fact Sheet by Argonne National Laboratory Environmental Assessment Division Depleted uranium (DU) normative value pilot study: levels of uranium in urine samples from the general population Archived 26 July 2011 at the Wayback Machine by A.D. Jones, B. G. Miller, S. Walker, J. Anderson, A. P. Colvin, P.A. Hutchison, C.A. Soutar.
== Terminology == Lactose intolerance primarily refers to a syndrome with one or more symptoms upon the consumption of food substances containing lactose sugar. Individuals may be lactose intolerant to varying degrees, depending on the severity of these symptoms. Hypolactasia is the term specifically for the small intestine producing little or no lactase enzyme. If a person with hypolactasia consumes lactose sugar, it results in lactose malabsorption. The digestive system is unable to process the lactose sugar, and the unprocessed sugars in the gut produce the symptoms of lactose intolerance. Lactose intolerance is not an allergy, because it is not an immune response, but rather a sensitivity to dairy caused by a deficiency of lactase enzyme. Milk allergy, occurring in about 2% of the population, is a separate condition, with distinct symptoms that occur when the presence of milk protein, whey, triggers an immune reaction. A milk allergy most often appears in the first year of life, while lactose intolerance typically appears later in life. Lauren Ornelas, the founder of Food Empowerment Project, has coined the term lactose normal to replace lactose intolerance, as the latter term suggests that there is something abnormal or medically pathological about it, and originated in a context of cultural bias and failure to recognize the fact that most weaned humans are unable to digest lactose. Some have expressed preference for the term lactose normal.
Arrived from Mexico on the blessed ground of this republic, whose executive powers were placed in your hands, I feel it my pleasant duty to present my respects and express my high admiration for your writings, your actions, and the liberalism of your ideas, which have inspired me from my earliest youth. I flatter myself in the expectation of expressing my sentiments orally to you, remitting at the same time the attached parcel, which my friend the Consul of the United States in Havana asked me to send to you[...] For moral reasons I could not resist seeing the United States and enjoying the consoling aspects of a people who under stand the precious gift of Liberty. I hope to be able to present my personal respects and admiration to one who contemplates philosophically the troubles of two continents. [...] I am quite unaware whether you know of me already through my work on galvanism and my publications in the memoirs of the Institut National in Paris. As a friend of science, you will excuse the indulgence of my admiration. I would love to talk to you about a subject that you have treated so ingeniously in your work on Virginia, the teeth of mammoth which we too dis covered in the Andes[...] During his wait for a response from President Jefferson, Humboldt was honored by the American Philosophical Society, of which Jefferson was the President. This society, founded in 1743 by Benjamin Franklin, was a center for scientific inquiry in the Republic. Humboldt mingled with members such as Dr.
Sources: en.wikipedia.org
== Evolution == There are five groups of TNNI in vertebrates, the extra two known as TNNI4 and TNNI5 (only found in non-amniotes). They are more similar to TNNI1 than to TNNI2 and TNNI3. Likewise, there are four groups of TNNT in vertebrates, with TNNT4 (only found in cartilaginous fishes, ray-finned fishes and lungfish) most closely resembling TNNT2. In most vertebrates and some non-vertebrate chordates, TNNI and TNNT genes tend to occur in pairs next to each other. It is likely that an ancestor to vertebrates had one such pair, which was duplicated into four during the two rounds of whole-genome duplication in early vertebrate evolution, with TNNT5 arising as an additional tandem dupliaction of TNNT4. Most vertebrates express TNNI1 and/or TNNI5 in the heart, whereas adult tetrapods (such as mammals) use TNNI3. Embryonic mammals use TNNI1 in the heart. In humans and teterapods in general, TNNI3 differ from the other TnI genes by having an N-termianl extension; a strikingly similar extension is found in the TNNI5 of cartilaginous, non-teleost ray-finned, and sarcopterygian fishes. Ray finned fishes do not have TNNI3 at all. Substituting TNNI3 for TNNI1 may confer increased tolerance to acidosis. Considering the similarity between TNNI and TNNT, the gene pair may have been the result of an even more ancient tandem duplication event.
=== Relationship with other guerrillas === The Hukhbalahap's methods were generally terrorist in nature; for example, Ray Hunt, an American who led his own band of 3,000 guerrillas, said of the Hukbalahap that
The head (Latin: caput). The head of the epididymis receives spermatozoa via the efferent ducts of the mediastinum of the testis at the superior pole of the testis. The head is characterized histologically by a thick epithelium with long stereocilia (described below) and a little smooth muscle. It is involved in absorbing fluid to make the sperm more concentrated. The concentration of the sperm here is dilute. The body (Latin: corpus). This has an intermediate epithelium and smooth muscle thickness. The tail (Latin: cauda). This has the thinnest epithelium of the three regions and the greatest quantity of smooth muscle. The tail is distally continuous with (the convoluted portion of) the ductus deferens (s. vas deferens).
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.